Research Paper Volume 16, Issue 2 pp 1925—1937

Figure 2. Melatonin improves brain tissue and neuronal damage caused by stroke. (A) In brain tissues, melatonin administration at doses of 5 and 10 mg/kg resulted in increased levels of SOD and GSH, while decreasing the level of MDA compared to the MCAO group. (B) Melatonin treatment at doses of 5 and 10 mg/kg reduced ROS accumulation in brain tissues when compared to the MCAO group. (C) The ACSL4 and MDM2 mRNA levels, as determined by qRT-PCR analysis, were compared between the groups treated with melatonin (at doses of 5 and 10 mg/kg) and the MCAO group. (D) The ACSL4 and MDM2 protein levels, as determined by WB analysis, were compared between the groups treated with melatonin (at doses of 5 and 10 mg/kg) and the MCAO group. (E) The protective effects of melatonin (at a dose of 10 mg/kg) on HT-22 cell viability were reversed by RSL3, as demonstrated by CCK-8 assay results. (F, G) The inhibitory effects of melatonin (at a dose of 10 mg/kg) on ROS and MDA levels in HT-22 cells were abolished by RSL3 according to ELISA assay findings. Data are presented as mean ± SD. ^*P < 0.05 vs. Con group; ^#P < 0.05 vs. MT treatment group.